India Lags China In Regional GMP Harmonization – ISPE Singapore
This article was originally published in PharmAsia News
China is actively seeking to enter a global agreement on good manufacturing processes for drugs while India remains aloof from a growing Asia movement on harmonization for inspections, training and rules in the industry.
You may also be interested in...
Asia Raises Bar for New Drugs, Manufacturers With Tougher CMC Reviews, GMP Inspections - A Look At Korea (Part 3)
South Korea's pharmaceutical regulatory program is in a state of change, and the Korea FDA is open to ongoing changes to support regulatory harmonization with the rest of the world. That openness presents an opportunity for industry to influence some differences between Korea and the rest of the world, according to said Jeffrey Ferguson, Eli Lilly's director of global regulatory affairs CMC
PharmAsia News looks ahead at 2015 to highlight expected trends and events shaping the biomedical community in Southeast Asia.
Southeast Asia in 2014 saw a continued push by several nations in the region to ink a Trans-Pacific Partnership pact that would potentially have a major impact on biological drugs. Also manufacturing and distribution saw a leap in the hub of Singapore as governments in the region ramped-up health spending.